CEO received an award of 65K ZBH derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Feb 20, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Feb 25, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001757216-26-000004
- Filed / recorded
Added to OQROOct 2, 2026, 12:29 PM UTC Data qualityVerified: identifiers matched exactly IssuerZIMMER BIOMET HOLDINGS, INC. Reporting personIvan Tornos RelationshipDirector, Officer Officer titleChairman, President and CEO SecurityRestricted Stock Units TableDerivative (Table II) Transaction dateFeb 20, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- Each RSU represents a contingent right to receive one share of Company common stock.
- Vests annually over three years in increments of one-third each year, commencing February 20, 2027.
Around the same time
Zimmer Biomet's SVP and CHRO sold $251K of Zimmer Biomet shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.